Tanuja Chitnis, M.D.
Affiliations: | Neurology | Harvard Medical School and Brigham and Women Hospital, Boston, MA, United States |
Area:
Multiple Sclerosis, Pediatric Multiple Sclerosis, Natural HistoryWebsite:
https://connects.catalyst.harvard.edu/profiles/profile/person/36152Google:
"Tanuja Chitnis"Mean distance: 18.73 (cluster 56)
Cross-listing: History of History Tree
Parents
Sign in to add mentorChildren
Sign in to add trainee
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Ziaei A, Solomon O, Casper TC, et al. (2024) Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585231224685 |
Ontaneda D, Chitnis T, Rammohan K, et al. (2023) Identification and management of subclinical disease activity in early multiple sclerosis: a review. Journal of Neurology |
Bose G, Healy BC, Saxena S, et al. (2023) Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity. Neurology(R) Neuroimmunology & Neuroinflammation. 10 |
Chitnis T. (2023) Navigating the challenges of diagnosing multiple sclerosis. The Lancet. Neurology. 22: 649-651 |
Chitnis T, Qureshi F, Gehman VM, et al. (2023) Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect disease activity in multiple sclerosis. Medrxiv : the Preprint Server For Health Sciences |
Malani Shukla N, Casper TC, Ness J, et al. (2023) Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments. Pediatric Neurology. 145: 125-131 |
Hobart J, Chitnis T, Oh J, et al. (2023) Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selection. Multiple Sclerosis and Related Disorders. 76: 104788 |
Gonzalez-Martinez A, Bose G, Lokhande H, et al. (2023) Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study. Journal of Neuroinflammation. 20: 136 |
Gonzalez-Martinez A, Patel R, Healy BC, et al. (2023) miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod. Journal of Neuroinflammation. 20: 131 |
Horton MK, Shim JE, Wallace A, et al. (2023) Rare and low-frequency coding genetic variants contribute to pediatric-onset multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 13524585221150736 |